(Q42488870)

1 November 2017

title

Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine (English)

1 reference

1 November 2017

3

Colao A

1 reference

1 November 2017

Merola B

1

1 reference

1 November 2017

Sarnacchiaro F

2

1 reference

1 November 2017

Di Somma C

4

1 reference

1 November 2017

Di Sarno A

5

1 reference

1 November 2017

Ferone D

6

1 reference

1 November 2017

Selleri A

7

1 reference

1 November 2017

Landi ML

8

1 reference

1 November 2017

Schettini G

9

1 reference

1 November 2017

Nappi C

10

1 reference

1 November 2017

publication date

1 September 1994

1 reference

Gynecological Endocrinology

1 November 2017

published in

1 reference

1 November 2017

volume

8

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

175-181

1 reference

Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Resistance to bromocriptine in prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205-502.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

CV 205–502 treatment of macroprolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

CV 205-502 treatment of hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599409072452

10.3109/09513599409072452

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference